Haw Par Corporation Ltd
SGX:H02

Watchlist Manager
Haw Par Corporation Ltd Logo
Haw Par Corporation Ltd
SGX:H02
Watchlist
Price: 11.81 SGD 0.08% Market Closed
Market Cap: 2.6B SGD

Relative Value

The Relative Value of one H02 stock under the Base Case scenario is 6.42 SGD. Compared to the current market price of 11.81 SGD, Haw Par Corporation Ltd is Overvalued by 46%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

H02 Relative Value
Base Case
6.42 SGD
Overvaluation 46%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
66
vs Industry
12
Median 3Y
11
Median 5Y
11.5
Industry
2.5
vs History
71
vs Industry
35
Median 3Y
12.4
Median 5Y
12.8
Industry
21.3
vs History
52
vs Industry
8
Median 3Y
48.3
Median 5Y
51
Industry
16.7
vs History
61
vs Industry
11
Median 3Y
45.5
Median 5Y
53.9
Industry
24.7
vs History
66
vs Industry
68
Median 3Y
0.6
Median 5Y
0.7
Industry
2.1
vs History
71
vs Industry
15
Median 3Y
9.1
Median 5Y
9.6
Industry
2.6
vs History
68
vs Industry
13
Median 3Y
16.6
Median 5Y
17.4
Industry
5.1
vs History
63
vs Industry
36
Median 3Y
32.4
Median 5Y
33.4
Industry
12.8
vs History
63
vs Industry
40
Median 3Y
36
Median 5Y
37.1
Industry
16.3
vs History
61
vs Industry
10
Median 3Y
41.2
Median 5Y
42.1
Industry
14.9
vs History
61
vs Industry
12
Median 3Y
75.6
Median 5Y
82
Industry
18.2
vs History
79
vs Industry
70
Median 3Y
0.6
Median 5Y
0.6
Industry
1.9

Multiples Across Competitors

H02 Competitors Multiples
Haw Par Corporation Ltd Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
SG
Haw Par Corporation Ltd
SGX:H02
2.6B SGD 10.7 11.5 26.7 29.2
US
Eli Lilly and Co
NYSE:LLY
699.1B USD 14.3 62.9 33.9 37
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
373.4B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.6 19.2 13.3 15.3
CH
Roche Holding AG
SIX:ROG
211.2B CHF 3.5 25.5 9.6 11.2
CH
Novartis AG
SIX:NOVN
184.2B CHF 4.2 17.4 10.3 13.8
UK
AstraZeneca PLC
LSE:AZN
166.2B GBP 4.1 28.8 131 197.5
US
Merck & Co Inc
NYSE:MRK
193.3B USD 3 11.1 8.3 10.1
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
133.5B USD 2.1 16.9 7.3 10.3
P/E Multiple
Earnings Growth PEG
SG
Haw Par Corporation Ltd
SGX:H02
Average P/E: 23.4
11.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
62.9
50%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.2
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.5
32%
0.8
CH
Novartis AG
SIX:NOVN
17.4
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.8
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.1
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.9
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SG
Haw Par Corporation Ltd
SGX:H02
Average EV/EBITDA: 396.4
26.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.9
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
13%
1
CH
Roche Holding AG
SIX:ROG
9.6
5%
1.9
CH
Novartis AG
SIX:NOVN
10.3
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.3
8%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SG
Haw Par Corporation Ltd
SGX:H02
Average EV/EBIT: 1 699.9
29.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.3
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.2
6%
1.9
CH
Novartis AG
SIX:NOVN
13.8
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.5
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.1
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
10%
1